Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens

Coşkun, Uğur; Kaya, Ali; Büyükberber, Süleyman; Benekli, Mustafa; Üner, Aytuğ; Dikilitaş, Mustafa; Öztürk, Bayram; Yıldız, Ramazan; Özkan, Seçil; Yaman, Emel; Yamaç, Deniz

doi:10.1007/s12032-007-9005-3

Cited by 4 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coskun et al study,21 patients treated with single agent gemcitabine as a secondline treatment and reported a partial response rate 19%, stabil disease rate 29%, median OS was 36 weeks. Only one patients experienced grade ¾ hemathologic toxicity in this study (Coskun et al, 2008).…”

Section: Discussionmentioning

confidence: 61%

See 1 more Smart Citation

Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Baykara¹,

Coşkun²,

Berk³

et al. 2012

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Purpose: The aim of this retrospective study was to determine response rates, progression-free survival (PFS), overall survival (OS) and toxicity of gemcitabine and paclitaxel combinations with advanced or metastatic non-small cell lung cancer patients (NSCLC) who have progressive disease after platinum-based first-line chemotherapy. Methods: We retrospectively evaluated the file records of patients treated with gemcitabine plus paclitaxel in advanced or metastatic NSCLC cases in a second-line setting. The chemotherapy schedule was as follows: gemcitabine 1500 mg/m 2 and paclitaxel 150 mg/m 2 administered every two weeks. Results: Forty-eight patients (45 male, 3 female) were evaluated; stage IIIB/IV 6/42; PS0, 8.3%, PS1, 72.9%, PS2, 18.8%; median age, 56 years old (range 38-76). Six (12.5%) patients showed a partial response (PR), 13 (27.1%) stable disease (SD), and 27 (56.3%) progressive disease (PD). The median OS was 6.63 months (95% CI 4.0-9.2); the median PFS was 2.7 months (95% CI 1.8-3.6). Grade 3 and 4 hematologic toxicities, including neutropenia (n=4, 8.4%), and anemia (n=3, 6.3%) were encountered, but no grade 3 or 4 thrombocytopenia. One patient developed febrile neutropenia. There were no interruption for reasons of toxicity and no exitus related to therapy. Conclusion: The combination of two-weekly gemcitabine plus paclitaxel was an effective and well-tolerated second-line chemotherapy regimen for advanced or metastatic NSCLC patients previously treated with platinum-containing chemotherapy. Although the most common and dose limiting toxicities were neutropenia and neuropathy, this regimen was tolerated well by the patients.

show abstract

Section: Discussionmentioning

confidence: 61%

“…Treatment-related death wasn't observed. Non-hemathologic toxicities are summarized in Table that median OS 17 weeks to 10 months, RR 0-38% (Hainsworth et al, 1995;Androulakis et al, 1998;Socinski et al, 1999;Bonomi et al, 2005;Coskun et al, 2008;Paz-Ares et al, 2008).…”

Section: Resultsmentioning

confidence: 99%

Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Baykara¹,

Coşkun²,

Berk³

et al. 2012

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

show abstract

“…In previous studies, overall response rate was between 18.5% and 19% in the treatment of single agent gemcitabine as a second treatment (Cho et al, 2006, Coskun et al, 2008. Overall response rate was higher in the group receiving docetaxel (12% vs 8%) and PFS and OS were longer in the gemcitabine group (but not istatistically sagnificant).…”

Section: Discussionmentioning

confidence: 86%

Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey

Yıldırım

Baha²,

Yurdakul³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To compare the efficacy and toxicity of gemcitabine versus docetaxel in a second-line setting of nonsmall cell lung cancer (NSCLC) patients previously treated with platin-based combination chemotherapy. Materials and Methods: We retrospectively evaluated the medical records of 57 patients treated with single agent gemcitabine or docetaxel in second-line setting of advanced NSCLC who received one prior platinumbased therapy. Results: The mean age was 56.7±8.39 years with 55 ( 96.5%) males and two (3.5%) females. Forty of them received docetaxel and 17 gemcitabine. The mean number of chemotherapy cycles was 6.8±4.0 in the gemcitabine group, while it was 4.6±3.0 in the docetaxel group. Overall response rates were 8% and 12% (P=0.02) for gemcitabine and docetaxel, respectively. The median survival time was 22 versus 21 months for gemcitabine and docetaxel, respectively. The median times to progression were 8 and 5 months. There was no difference between the two groups in terms of incidence of adverse affects (40% vs 47.1%). All of the hematological side effects were grade 1/2. No major toxicity was encountered necessitating stopping the drug for either group. Conclusions: Treatment with gemcitabine demonstrated clinically equivalent efficacy with a significantly improved safety profile compared with those receiving docetaxel in the second-line setting for advanced NSCLC in this study. Based on these results, treatment with gemcitabine should be considered a standard treatment option for second-line NSCLC.

show abstract

“…60 Subsequent studies demonstrated that pemetrexed was as effective as docetaxel in the second-line setting but was less toxic. 61 Gemcitabine also may be of some value in this setting, 62 whereas vinorelbine appears to be ineffective. 63 Targeted Therapies in Non-Small Cell Lung Cancer Targeted therapies are based on the use of drugs or other agents that are directed specifically against a cell growth receptor or its ligands, signaling pathway components, or other effectors of function.…”

Section: Chemotherapy In Previously Treated Patients With Advanced Nomentioning

confidence: 99%

Clinical Management of Lung Cancer

Stewart

2010

Tumors and Tumor-Like Conditions of the Lung and Pleura

View full text Add to dashboard Cite

Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens

Cited by 4 publications

References 13 publications

Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey

Clinical Management of Lung Cancer

Contact Info

Product

Resources

About